📣 VC round data is live. Check it out!

InspireMD Valuation Multiples

Discover revenue and EBITDA valuation multiples for InspireMD and similar public comparables like Mentice, HeartBeam, OssDsign, Elutia and more.

InspireMD Overview

About InspireMD

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.


Founded

2008

HQ

United States

Employees

86

Financials (LTM)

Revenue: $10M
EBITDA: ($44M)

EV

$9M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

InspireMD Financials

InspireMD reported last 12-month revenue of $10M and negative EBITDA of ($44M).

In the same LTM period, InspireMD generated $2M in gross profit, ($44M) in EBITDA losses, and had net loss of ($55M).

Revenue (LTM)


InspireMD P&L

In the most recent fiscal year, InspireMD reported revenue of $9M and EBITDA of ($38M).

InspireMD is unprofitable as of last fiscal year, with gross margin of 30%, EBITDA margin of (419%), and net margin of (543%).

See analyst estimates for InspireMD
LTMLast FY202320242025202620272028
Revenue$10M$9M$6M$7M$9M
Gross Profit$2M$3M$2M$2M$3M
Gross Margin24%30%29%21%30%
EBITDA($44M)($38M)($21M)($33M)($49M)
EBITDA Margin(461%)(419%)(337%)(474%)(547%)
EBIT Margin(582%)(553%)(341%)(478%)(553%)
Net Profit($55M)($49M)($20M)($32M)($49M)
Net Margin(573%)(543%)(321%)(457%)(543%)

Financial data powered by Morningstar, Inc.

InspireMD Stock Performance

InspireMD has current market cap of $47M, and enterprise value of $9M.

Market Cap Evolution


InspireMD's stock price is $1.01.

InspireMD share price decreased by 15.1% in the last 30 days, and by 60.5% in the last year.

InspireMD has an EPS (earnings per share) of $-1.04.

See more trading valuation data for InspireMD
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$9M$47M0.0%-15.1%-43.3%-60.5%$-1.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

InspireMD Valuation Multiples

InspireMD trades at 0.9x EV/Revenue multiple, and (0.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for InspireMD

EV / Revenue (LTM)


InspireMD Financial Valuation Multiples

As of May 26, 2026, InspireMD has market cap of $47M and EV of $9M.

InspireMD has a P/E ratio of (0.9x).

LTMLast FY202320242025202620272028
EV/Revenue0.9x1.0x1.4x1.3x1.0x
EV/EBITDA(0.2x)(0.2x)(0.4x)(0.3x)(0.2x)
EV/EBIT(0.2x)(0.2x)(0.4x)(0.3x)(0.2x)
EV/Gross Profit3.8x3.3x4.9x5.9x3.3x
P/E(0.9x)(1.0x)(2.4x)(1.5x)(1.0x)
EV/FCF(0.2x)(0.5x)(0.4x)(0.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified InspireMD Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

InspireMD Margins & Growth Rates

InspireMD grew revenue by 16% and EBITDA by 42% in the last fiscal year.

In the most recent fiscal year, InspireMD reported gross margin of 30%, EBITDA margin of (419%), and net margin of (543%).

See estimated margins and future growth rates for InspireMD

InspireMD Margins

Last FY202420252026202720282029
Gross Margin30%21%30%17%
EBITDA Margin(419%)(474%)(547%)(514%)
EBIT Margin(553%)(478%)(553%)(619%)
Net Margin(543%)(457%)(543%)(613%)
FCF Margin(409%)(332%)(409%)

InspireMD Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth16%13%28%16%
Gross Profit Growth(34%)(17%)76%(34%)
EBITDA Growth42%59%48%9%
EBIT Growth29%58%48%29%
Net Profit Growth30%61%52%30%
FCF Growth39%58%

Data powered by FactSet, Inc. and Morningstar, Inc.

InspireMD Operational KPIs

InspireMD's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.6M for the same period.

InspireMD's Rule of 40 is (499%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

InspireMD's Rule of X is (476%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for InspireMD
LTMLast FY202320242025202620272028
Rule of 40(404%)(499%)
Bessemer Rule of X(318%)(476%)
Revenue per Employee$0.1M
Opex per Employee$0.6M
S&M Expenses to Revenue205%185%62%87%184%
G&A Expenses to Revenue215%231%179%218%231%
R&D Expenses to Revenue186%167%129%195%167%
Opex to Revenue582%370%499%582%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

InspireMD Competitors

InspireMD competitors include Mentice, HeartBeam, OssDsign, Elutia, Nutriband, Singular Health, SciBase Holding, Baumer, Baird Medical Investment and K Pharma.

Most InspireMD public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Mentice1.4x1.3x88.9x33.1x
HeartBeam119.6x(2.2x)
OssDsign1.5x1.6x(7.4x)(6.7x)
Elutia2.1x2.1x(2.0x)(1.8x)
Nutriband14.6x14.6x(5.0x)
Singular Health249.9x(8.3x)
SciBase Holding10.5x8.4x(5.2x)(5.6x)
Baumer0.8x3.8x

This data is available for Pro users. Sign up to see all InspireMD competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About InspireMD

When was InspireMD founded?InspireMD was founded in 2008.
Where is InspireMD headquartered?InspireMD is headquartered in United States.
How many employees does InspireMD have?As of today, InspireMD has over 86 employees.
Who is the CEO of InspireMD?InspireMD's CEO is Marvin Slosman.
Is InspireMD publicly listed?Yes, InspireMD is a public company listed on Nasdaq.
What is the stock symbol of InspireMD?InspireMD trades under NSPR ticker.
When did InspireMD go public?InspireMD went public in 1997.
Who are competitors of InspireMD?InspireMD main competitors include Mentice, HeartBeam, OssDsign, Elutia, Nutriband, Singular Health, SciBase Holding, Baumer, Baird Medical Investment, K Pharma.
What is the current market cap of InspireMD?InspireMD's current market cap is $47M.
What is the current revenue of InspireMD?InspireMD's last 12 months revenue is $10M.
What is the current revenue growth of InspireMD?InspireMD revenue growth (NTM/LTM) is 57%.
What is the current EV/Revenue multiple of InspireMD?Current revenue multiple of InspireMD is 0.9x.
Is InspireMD profitable?No, InspireMD is not profitable.
What is the current EBITDA of InspireMD?InspireMD has negative EBITDA and is not profitable.
What is InspireMD's EBITDA margin?InspireMD's last 12 months EBITDA margin is (461%).
What is the current EV/EBITDA multiple of InspireMD?Current EBITDA multiple of InspireMD is (0.2x).
How many companies InspireMD has acquired to date?InspireMD hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies InspireMD has invested to date?InspireMD hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to InspireMD

Lists including InspireMD

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial